Chris R Triggle

List of Publications by Year
in descending order

56 papers	4,488 citations	136950 32 h-index	168389 53 g-index
57 all docs	57 docs citations	57 times ranked	5954 citing authors

#	Article	IF	Citations
1	Metformin: Is it a drug for all reasons and diseases?. Metabolism: Clinical and Experimental, 2022, 133, 155223.	3.4	92
2	Metformin Prevents Hyperglycemia-Associated, Oxidative Stress-Induced Vascular Endothelial Dysfunction: Essential Role for the Orphan Nuclear Receptor Human Nuclear Receptor 4A1 (Nur77). Molecular Pharmacology, 2021, 100, 428-455.	2.3	17
3	A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan. Frontiers in Endocrinology, 2021, 12, 718942.	3.5	107
4	Why the endothelium? The endothelium as a target to reduce diabetes-associated vascular disease. Canadian Journal of Physiology and Pharmacology, 2020, 98, 415-430.	1.4	36
5	Treatment with a Combination of Metformin and 2-Deoxyglucose Upregulates Thrombospondin-1 in Microvascular Endothelial Cells: Implications in Anti-Angiogenic Cancer Therapy. Cancers, 2019, 11, 1737.	3.7	21
6	Exercise Alleviates Obesity-Induced Metabolic Dysfunction via Enhancing FGF21 Sensitivity in Adipose Tissues. Cell Reports, 2019, 26, 2738-2752.e4.	6.4	115
7	Minimizing Hyperglycemia-Induced Vascular Endothelial Dysfunction by Inhibiting Endothelial Sodium-Glucose Cotransporter 2 and Attenuating Oxidative Stress: Implications for Treating Individuals With Type 2 Diabetes. Canadian Journal of Diabetes, 2019, 43, 510-514.	0.8	23
8	Metformin: The Answer to Cancer in a Flower? Current Knowledge and Future Prospects of Metformin as an Anti-Cancer Agent in Breast Cancer. Biomolecules, 2019, 9, 846.	4.0	60
9	Impact of currently used anti-diabetic drugs on myoendothelial communication. Current Opinion in Pharmacology, 2019, 45, 1-7.	3.5	8
10	Hyperglycaemic impairment of PAR2-mediated vasodilation: Prevention by inhibition of aortic endothelial sodium-glucose-co-Transporter-2 and minimizing oxidative stress. Vascular Pharmacology, 2018, 109, 56-71.	2.1	84
11	Metformin represses glucose starvation induced autophagic response in microvascular endothelial cells and promotes cell death. Biochemical Pharmacology, 2017, 132, 118-132.	4.4	34
12	Molecular Interplay between microRNA-34a and Sirtuin1 in Hyperglycemia-Mediated Impaired Angiogenesis in Endothelial Cells: Effects of Metformin. Journal of Pharmacology and Experimental Therapeutics, 2016, 356, 314-323.	2.5	78
13	MicroRNA Signature and Cardiovascular Dysfunction. Journal of Cardiovascular Pharmacology, 2015, 65, 419-429.	1.9	31
14	Metformin: An Old Drug for the Treatment of Diabetes but a New Drug for the Protection of the Endothelium. Medical Principles and Practice, 2015, 24, 401-415.	2.4	1,060
15	Metformin improves endothelial function in aortic tissue and microvascular endothelial cells subjected to diabetic hyperglycaemic conditions. Biochemical Pharmacology, 2015, 98, 412-421.	4.4	40
16	Cardiovascular impact of drugs used in the treatment of diabetes. Therapeutic Advances in Chronic Disease, 2014, 5, 245-268.	2.5	54
17	Metformin modulates hyperglycaemiaâ€induced endothelial senescence and apoptosis through <scp>SIRT1</scp>. British Journal of Pharmacology, 2014, 171, 523-535.	5.4	193
18	FGF21 Maintains Glucose Homeostasis by Mediating the Cross Talk Between Liver and Brain During Prolonged Fasting. Diabetes, 2014, 63, 4064-4075.	0.6	217

#	Article	IF	Citations
19	Peroxynitrite Biology. , 2014, , 207-242.		6
20	Endothelial Dysfunction in Diabetes Mellitus: Possible Involvement of Endoplasmic Reticulum Stress?. Experimental Diabetes Research, 2012, 2012, 1-14.	3.8	98
21	The endothelium: influencing vascular smooth muscle in many ways. Canadian Journal of Physiology and Pharmacology, 2012, 90, 713-738.	1.4	188
22	The endothelium in compliance and resistance vessels. Frontiers in Bioscience - Scholar, 2011, S3, 730-744.	2.1	25
23	Endothelial dysfunction in diabetes: multiple targets for treatment. Pflugers Archiv European Journal of Physiology, 2010, 459, 977-994.	2.8	89
24	A review of endothelial dysfunction in diabetes: a focus on the contribution of a dysfunctional eNOS. Journal of the American Society of Hypertension, 2010, 4, 102-115.	2.3	84
25	A role for nitroxyl (HNO) as an endotheliumâ€derived relaxing and hyperpolarizing factor in resistance arteries. British Journal of Pharmacology, 2009, 157, 540-550.	5.4	110
26	Effects of a Western diet versus high glucose on endothelium-dependent relaxation in murine micro- and macro-vasculature. European Journal of Pharmacology, 2008, 601, 111-117.	3.5	31
27	Vascular dysfunction in type 2 diabetic TallyHo mice: role for an increase in the contribution of PGH2/TxA2 receptor activation and cytochrome p450 productsThis paper is one of a selection of papers published in this Special Issue, entitled The Cellular and Molecular Basis of Cardiovascular Dysfunction, Dhalla 70th Birthday Tribute.. Canadian Journal of Physiology and Pharmacology, 2007, 85, 404-412.	1.4	23
28	Oxidative stress and increased eNOS and NADPH oxidase expression in mouse microvessel endothelial cells. Journal of Cellular Physiology, 2007, 212, 682-689.	4.1	89
29	Nitrosothiol stores in vascular tissue: Modulation by ultraviolet light, acetylcholine and ionomycin. European Journal of Pharmacology, 2007, 560, 183-192.	3.5	24
30	Pharmacological characteristics of endothelium-derived hyperpolarizing factor-mediated relaxation of small mesenteric arteries from db/db mice. European Journal of Pharmacology, 2006, 551, 98-107.	3.5	48
31	A Nonthiazolidinedione Peroxisome Proliferator-Activated Receptor Î³ Agonist Reverses Endothelial Dysfunction in Diabetic (db/db-/-) Mice. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 364-370.	2.5	9
32	Enhanced vascular reactivity of small mesenteric arteries from diabetic mice is associated with enhanced oxidative stress and cyclooxygenase products. British Journal of Pharmacology, 2005, 144, 953-960.	5.4	84
33	Twenty-five years since the discovery of endothelium-derived relaxing factor (EDRF): does a dysfunctional endothelium contribute to the development of type 2 diabetes?. Canadian Journal of Physiology and Pharmacology, 2005, 83, 681-700.	1.4	26
34	Endothelial dysfunction in Type 2 diabetes correlates with deregulated expression of the tail-anchored membrane protein SLMAP. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 289, H206-H211.	3.2	20
35	The vascular endothelium in diabetes: a practical target fordrug treatment?. Expert Opinion on Therapeutic Targets, 2005, 9, 101-117.	3.4	20
36	Endothelial cell dysfunction and the vascular complications associated with type 2 diabetes: assessing the health of the endothelium. Vascular Health and Risk Management, 2005, 1, 55-71.	2.3	95

#	Article	IF	Citations
37	2-Furoyl-LIGRLO-amide: A Potent and Selective Proteinase-Activated Receptor 2 Agonist. Journal of Pharmacology and Experimental Therapeutics, 2004, 309, 1124-1131.	2.5	128
38	The endothelium in health and disease: A discussion of the contribution of non-nitric oxide endothelium-derived vasoactive mediators to vascular homeostasis in normal vessels and in type II diabetes. Molecular and Cellular Biochemistry, 2004, 263, 21-27.	3.1	27
39	Hyperpolarization of murine small caliber mesenteric arteries by activation of endothelial proteinase-activated receptor 2. Canadian Journal of Physiology and Pharmacology, 2004, 82, 1103-1112.	1.4	35
40	Endothelium-Derived Hyperpolarizing Factor(s). Does it Exist and What Role Does it Play in the Regulation of Blood Flow?. Progress in Experimental Cardiology, 2004, , 341-348.	0.0	0
41	Endothelial cell dysfunction in type I and II diabetes: The cellular basis for dysfunction. Drug Development Research, 2003, 58, 28-41.	2.9	11
42	Searching for the physiological role and therapeutic potential of vascular proteinase-activated receptor-2 (PAR2). Drug Development Research, 2003, 60, 14-19.	2.9	2
43	A photosensitive vascular smooth muscle store of nitric oxide in mouse aorta: no dependence on expression of endothelial nitric oxide synthase. British Journal of Pharmacology, 2003, 138, 932-940.	5.4	28
44	Chronic oral supplementation with sepiapterin prevents endothelial dysfunction and oxidative stress in small mesenteric arteries from diabetic (db/db) mice. British Journal of Pharmacology, 2003, 140, 701-706.	5.4	86
45	Catalase has negligible inhibitory effects on endothelium-dependent relaxations in mouse isolated aorta and small mesenteric artery. British Journal of Pharmacology, 2003, 140, 1193-1200.	5.4	63
46	Endothelium-derived reactive oxygen species: their relationship to endothelium-dependent hyperpolarization and vascular tone. Canadian Journal of Physiology and Pharmacology, 2003, 81, 1013-1028.	1.4	76
47	The Endothelium in Health and Disease-A Target for Therapeutic Intervention.. Journal of Smooth Muscle Research, 2003, 39, 249-267.	1.2	90
48	Proteinase-Activated Receptor-2 (PAR2): Vascular Effects of a PAR2-Derived Activating Peptide via a Receptor Different than PAR2. Journal of Pharmacology and Experimental Therapeutics, 2002, 303, 985-992.	2.5	36
49	Endotheliumâ€Derived Hyperpolarizing Factor: Is There A Novel Chemical Mediator?. Clinical and Experimental Pharmacology and Physiology, 2002, 29, 153-160.	1.9	42
50	Multiple mechanisms of vascular smooth muscle relaxation by the activation of Proteinase-Activated Receptor 2 in mouse mesenteric arterioles. British Journal of Pharmacology, 2002, 135, 155-169.	5.4	76
51	Cellular basis of endothelial dysfunction in small mesenteric arteries from spontaneously diabetic (<i>db/db</i>â^’/â^’) mice: role of decreased tetrahydrobiopterin bioavailability. British Journal of Pharmacology, 2002, 136, 255-263.	5.4	164
52	NO and the vasculature: where does it come from and what does it do?. Heart Failure Reviews, 2002, 7, 423-445.	3.9	26
53	Endothelium-derived relaxing factors: A focus on endothelium-derived hyperpolarizing factor(s). Canadian Journal of Physiology and Pharmacology, 2001, 79, 443-470.	1.4	146
54	Novel endothelium-derived relaxing factors. Journal of Pharmacological and Toxicological Methods, 2000, 44, 441-452.	0.7	22

#	Article	IF	Citations
55	Desensitization of a-Adrenoceptor Mediated Responses in Vascular Smooth Muscle. , 1996, , 119-138.		0
56	Role of NO in vascular smooth muscle and cardiac muscle function. Trends in Pharmacological Sciences, 1994, 15, 255-259.	8.7	90